Pancreatic Neuroendocrine Tumors (PNETs): Role of Endoscopic UltraSound-Fine Needle Aspiration (EUS-FNA) and Accuracy of Ki-67 Measurement on Cytological Specimens Abstract #859

Introduction: The role of EUS-FNA in preoperative diagnosis and grading of pNETs is well-established, but it is unclear how Ki-67 expression on cytological specimens obtained by EUS-FNA reflects the value found on surgical specimens.
Aim(s): To report our experience, to describe the feasibility of measurement of Ki-67 on cytological samples, to evaluate its accuracy if compared with the Ki-67 measurement on surgical specimens.
Materials and methods: Retrospective analysis of all cases of pNETs diagnosed by means of EUS-FNA from August 2003. Cytological Ki-67 expression was compared with definitive surgical Ki-67 results.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Claudio G De Angelis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#3036 Can Ki-67 with 5.5% Be Better in Predicting Prognosis for Well Differentiated Pancreatic Neuroendocrine Tumors?
Introduction: Pancreatic neuroendocrine tumors (NETs) are rare malignancies, Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis of neuroendocrine tumors. However, the ideal grading method for G1/G2 remains controversial.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Prof. Huang-Ying Tan
Authors: Yuan B, Chen Y Y, Zhang P, Wang X, ...
#2926 O-Positive Blood Group Is Associated with Prolonged Recurrence-Free Survival Following Pancreatic Neuroendocrine Tumor (PanNET) Curative-Intent Surgical Resection
Introduction: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of pancreatic adenocarcinoma is better in patients with blood group O. This has not been extensively explored in PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Louis de Mestier
#2733 Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours
Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Anja Rinke
#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
#2852 Diagnostic Accuracy of Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) in the Evaluation of Pancreatic Neuroendocrine Neoplasms (PNEN) Grading
Introduction: Prognosis of pNENs depends on staging and grading, based on the cyto-histological Ki67 labelling; EUS-FNA is considered the gold standard technique to obtain it in pre-therapeutic setting
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Matteo Tacelli